Leuven, Belgium - 26 August, 2014 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, issued an update on business and financial progress in the first half of this year today.
"We made significant progress in the first half of 2014," said Eduardo Bravo, CEO of TiGenix. "We have transformed the operations of TiGenix to enable the company to fully focus on realising the value in its development pipeline. Our Phase III trial of Cx601 is on track to deliver results earlier than anticipated, and our intravenously administered stem cell product, Cx611, has been endorsed by international clinical experts to move forward in two areas of high unmet medical need and significant commercial potential, early rheumatoid arthritis and severe sepsis."
TiGenix expects to take the following steps within the next 12 to 18 months:
The review of the statutory auditors, BDO Bedrijfsrevisoren Burg. Ven. CBVA, can be found in the Condensed Consolidated Financial Statements for H1 2014 in the investor section of the TiGenix website, www.tigenix.com
The interim financial statements for H1 2014 can be found in the investor section of the TiGenix website, www.tigenix.com
On Tuesday, 26 August, at 15:00h CEST/9.00am EDT, TiGenix will conduct a conference call webcast. The following speakers will present more details on this half year update, and will take questions:
The webcast can be followed live online via the link:
http://www.media-server.com/m/p/4snzq4rq
The press release and the webcast slide presentation will be made available in the Newsroom section of the TiGenix website. A replay of the webcast will be available on the website shortly after the live webcast has finished.
Richard Simpson
Senior Consultant, Comfi sprl
T: +32 494 578 278
richard@comfi.be
Source: TiGenix news